C1S and hereditary angioedema: HAE attacks that do not meet eligibility criteria may be treated with conventional on‐demand treatment (including plasma‐derived C1‐inhibitor, recombinant human C1‐esterase inhibitor, icatibant, and ecallantide) per the patient's usual treatment regimen.